An Update on Iron Chelation Therapy

Overview

Journal Blood Transfus

Specialty Hematology

Date 2012 Jul 14

PMID 22790257

Citations 102

Authors

Erika Poggiali

Elena Cassinerio

Laura Zanaboni

Maria Domenica Cappellini

Affiliations

Soon will be listed here.

Citing Articles

Erythrocytapheresis as a strategy to manage anemia and iron overload in nondeletional hemoglobin H disease.

Zhang K, Bliamptis J, Park J, Kopko P, Sanchez A, Gopal S EJHaem. 2025; 6(1):e21089.

PMID: 39866926 PMC: 11756960. DOI: 10.1002/jha2.1089.

Ferroptosis in Osteoarthritis: Current Understanding.

Liu Y, Zhang Z, Fang Y, Liu C, Zhang H J Inflamm Res. 2024; 17:8471-8486.

PMID: 39529997 PMC: 11552513. DOI: 10.2147/JIR.S493001.

Case report: Acute liver failure during deferasirox therapy and the potential role of pharmacogenetics.

Garcia-Farina B, Rink L, Santarini V, Westkemper M, Dohna-Schwake C, Mohlendick B Front Pharmacol. 2024; 15:1477755.

PMID: 39508042 PMC: 11538451. DOI: 10.3389/fphar.2024.1477755.

Effects of Dietary Supplements on Iron-Loading Susceptibility Artefacts in Pelvic MRI.

Samuels J, Martin J, Richardson M, Skehan K Cureus. 2024; 16(7):e65605.

PMID: 39205737 PMC: 11350153. DOI: 10.7759/cureus.65605.

Skin complications during iron chelation therapy for beta-thalassemia: overview and treatment approach.

Saeidnia M, Shadfar F, Sharifi S, Babashahi M, Ghaderi A, Shokri M Int J Hematol. 2024; 120(3):271-277.

PMID: 39088188 DOI: 10.1007/s12185-024-03825-w.

References

Brittenham G, Griffith P, Nienhuis A, McLaren C, Young N, Tucker E . Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994; 331(9):567-73. DOI: 10.1056/NEJM199409013310902. View

Addis A, Loebstein R, Koren G, Einarson T . Meta-analytic review of the clinical effectiveness of oral deferiprone (L1). Eur J Clin Pharmacol. 1999; 55(1):1-6. DOI: 10.1007/s002280050584. View

Taher A, El-Beshlawy A, Elalfy M, Al Zir K, Daar S, Habr D . Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study. Eur J Haematol. 2009; 82(6):458-65. PMC: 2730551. DOI: 10.1111/j.1600-0609.2009.01228.x. View

Davis B, Porter J . Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood. 2000; 95(4):1229-36. View

Daar S, Pathare A . Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload. Ann Hematol. 2006; 85(5):315-9. DOI: 10.1007/s00277-005-0075-z. View

Porter J, Lin K, Beris P, Forni G, Taher A, Habr D . Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias. Eur J Haematol. 2011; 87(4):338-48. PMC: 3229702. DOI: 10.1111/j.1600-0609.2011.01660.x. View

Delea T, Edelsberg J, Sofrygin O, Thomas S, Baladi J, Phatak P . Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion. 2007; 47(10):1919-29. DOI: 10.1111/j.1537-2995.2007.01416.x. View

Berdoukas V, Chouliaras G, Moraitis P, Zannikos K, Berdoussi E, Ladis V . The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study. J Cardiovasc Magn Reson. 2009; 11:20. PMC: 2713224. DOI: 10.1186/1532-429X-11-20. View

Wells R, Leber B, Buckstein R, Lipton J, Hasegawa W, Grewal K . Iron overload in myelodysplastic syndromes: a Canadian consensus guideline. Leuk Res. 2008; 32(9):1338-53. DOI: 10.1016/j.leukres.2008.02.021. View

10.

Link G, Konijn A, Breuer W, Cabantchik Z, Hershko C . Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture. J Lab Clin Med. 2001; 138(2):130-8. DOI: 10.1067/mlc.2001.116487. View

11.

Berdoukas V, Farmaki K, Wood J, Coates T . Iron chelation in thalassemia: time to reconsider our comfort zones. Expert Rev Hematol. 2011; 4(1):17-26. DOI: 10.1586/ehm.10.74. View

12.

Wood J . Cardiac iron across different transfusion-dependent diseases. Blood Rev. 2008; 22 Suppl 2:S14-21. PMC: 2896332. DOI: 10.1016/S0268-960X(08)70004-3. View

13.

Galanello R, Piga A, Alberti D, Rouan M, Bigler H, Sechaud R . Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. J Clin Pharmacol. 2003; 43(6):565-72. View

14.

Morado M, Ojeda E, Garcia-Bustos J, Aguado M, Arrieta R, Quevedo E . BMT: Serum Ferritin as Risk Factor for Veno-occlusive Disease of the Liver. Prospective Cohort Study. Hematology. 2001; 4(6):505-512. View

15.

Gattermann N, Rachmilewitz E . Iron overload in MDS-pathophysiology, diagnosis, and complications. Ann Hematol. 2010; 90(1):1-10. DOI: 10.1007/s00277-010-1091-1. View

16.

Anderson L, Wonke B, Prescott E, Holden S, Walker J, Pennell D . Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet. 2002; 360(9332):516-20. DOI: 10.1016/s0140-6736(02)09740-4. View

17.

Deugnier Y, Turlin B, Ropert M, Cappellini M, Porter J, Giannone V . Improvement in liver pathology of patients with β-thalassemia treated with deferasirox for at least 3 years. Gastroenterology. 2011; 141(4):1202-11, 1211.e1-3. DOI: 10.1053/j.gastro.2011.06.065. View

18.

Henter J, Karlen J . Fatal agranulocytosis after deferiprone therapy in a child with Diamond-Blackfan anemia. Blood. 2007; 109(12):5157-9. DOI: 10.1182/blood-2007-02-065805. View

19.

Miceli M, Dong L, Grazziutti M, Fassas A, Thertulien R, van Rhee F . Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients. Bone Marrow Transplant. 2006; 37(9):857-64. DOI: 10.1038/sj.bmt.1705340. View

20.

Sheppard L, Nortey P, Wonke B, Hoffbrand A . Pharmacokinetics of the oral iron chelator deferiprone (L1) in patients with iron overload. Br J Haematol. 1995; 89(2):403-8. DOI: 10.1111/j.1365-2141.1995.tb03318.x. View